Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 62

1.

KRAS mutations predict response to EGFR inhibitors.

Raponi M, Winkler H, Dracopoli NC.

Curr Opin Pharmacol. 2008 Aug;8(4):413-8. doi: 10.1016/j.coph.2008.06.006. Epub 2008 Jul 19. Review.

PMID:
18619559
2.

KRAS mutational testing in the selection of patients for EGFR-targeted therapies.

Garcia J, Riely GJ, Nafa K, Ladanyi M.

Semin Diagn Pathol. 2008 Nov;25(4):288-94. Review.

PMID:
19013894
3.

KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program.

van Krieken JH, Jung A, Kirchner T, Carneiro F, Seruca R, Bosman FT, Quirke P, Fléjou JF, Plato Hansen T, de Hertogh G, Jares P, Langner C, Hoefler G, Ligtenberg M, Tiniakos D, Tejpar S, Bevilacqua G, Ensari A.

Virchows Arch. 2008 Nov;453(5):417-31. doi: 10.1007/s00428-008-0665-y. Epub 2008 Sep 18. Review. Erratum in: Virchows Arch. 2009 Feb;454(2):233-5.

PMID:
18802721
4.

KRAS mutation testing in colorectal cancer.

Plesec TP, Hunt JL.

Adv Anat Pathol. 2009 Jul;16(4):196-203. doi: 10.1097/PAP.0b013e3181a9d4ed. Review.

PMID:
19546608
5.

Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.

Neumann J, Zeindl-Eberhart E, Kirchner T, Jung A.

Pathol Res Pract. 2009;205(12):858-62. doi: 10.1016/j.prp.2009.07.010. Epub 2009 Aug 12.

PMID:
19679400
6.

KRAS mutational status as a predictor of epidermal growth factor receptor inhibitor efficacy in colorectal cancer.

Baynes RD, Gansert J.

Am J Ther. 2009 Nov-Dec;16(6):554-61. doi: 10.1097/MJT.0b013e318199fa17. Review.

PMID:
19352138
7.

KRAS mutation testing of colorectal cancer for anti-EGFR therapy: dogmas versus evidence.

Tímár J, Hegedüs B, Rásó E.

Curr Cancer Drug Targets. 2010 Dec;10(8):813-23. Review.

PMID:
20718705
8.

The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer.

Lopez-Chavez A, Carter CA, Giaccone G.

Curr Opin Investig Drugs. 2009 Dec;10(12):1305-14. Review.

PMID:
19943202
9.

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD.

J Clin Oncol. 2008 Apr 1;26(10):1626-34. doi: 10.1200/JCO.2007.14.7116. Epub 2008 Mar 3.

10.

KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay.

Auner V, Kriegshäuser G, Tong D, Horvat R, Reinthaller A, Mustea A, Zeillinger R.

BMC Cancer. 2009 Apr 9;9:111. doi: 10.1186/1471-2407-9-111.

11.

Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer.

Sánchez-Muñoz A, Gallego E, de Luque V, Pérez-Rivas LG, Vicioso L, Ribelles N, Lozano J, Alba E.

BMC Cancer. 2010 Apr 13;10:136. doi: 10.1186/1471-2407-10-136.

12.

EGFR and KRAS mutations in patients with adenocarcinoma of the lung.

Jang TW, Oak CH, Chang HK, Suo SJ, Jung MH.

Korean J Intern Med. 2009 Mar;24(1):48-54. doi: 10.3904/kjim.2009.24.1.43.

13.

Use of K-Ras as a predictive biomarker for selecting anti-EGF receptor/pathway treatment.

Jiang Y, Mackley H, Cheng H, Ajani JA.

Biomark Med. 2010 Aug;4(4):535-41. doi: 10.2217/bmm.10.74. Review.

PMID:
20701442
14.

[Predictive biomarkers in colorectal cancer].

Bosman FT.

Rev Med Suisse. 2009 Jul 15;5(211):1513-8. French.

PMID:
19694362
15.

A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases.

Monaco SE, Nikiforova MN, Cieply K, Teot LA, Khalbuss WE, Dacic S.

Hum Pathol. 2010 Jan;41(1):94-102. doi: 10.1016/j.humpath.2009.06.019. Epub 2009 Sep 8.

PMID:
19740513
16.
17.

Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities.

Modjtahedi H, Essapen S.

Anticancer Drugs. 2009 Nov;20(10):851-5. doi: 10.1097/CAD.0b013e3283330590. Review.

PMID:
19826350
18.

Individualized therapies in colorectal cancer: KRAS as a marker for response to EGFR-targeted therapy.

Chang DZ, Kumar V, Ma Y, Li K, Kopetz S.

J Hematol Oncol. 2009 Apr 22;2:18. doi: 10.1186/1756-8722-2-18. Review.

19.

High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice.

Santini D, Loupakis F, Vincenzi B, Floriani I, Stasi I, Canestrari E, Rulli E, Maltese PE, Andreoni F, Masi G, Graziano F, Baldi GG, Salvatore L, Russo A, Perrone G, Tommasino MR, Magnani M, Falcone A, Tonini G, Ruzzo A.

Oncologist. 2008 Dec;13(12):1270-5. doi: 10.1634/theoncologist.2008-0181. Epub 2008 Dec 4.

20.

Personalized medicine enters the US marketplace: KRAS, anti-EGFR monoclonal antibodies, and colon cancer.

Lieberman R.

Am J Ther. 2009 Nov-Dec;16(6):477-9. doi: 10.1097/MJT.0b013e3181baf276. No abstract available.

PMID:
19829092
Items per page

Supplemental Content

Write to the Help Desk